<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416959</url>
  </required_header>
  <id_info>
    <org_study_id>0012807</org_study_id>
    <nct_id>NCT03416959</nct_id>
  </id_info>
  <brief_title>Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones</brief_title>
  <acronym>BMD</acronym>
  <official_title>Prospective Bone Metastases Database</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to collect prospective data on the natural history of bone
      metastases (BMs) and skeleta related events (SREs),
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are to evaluate clinical and biological factors of patients with BMs
      after reconstruction with intramedullary fixation (IMN) or endoprosthetic reconstruction
      (EPR) with a specific focus on (1) the rate of complication or failure; (2) differences in
      complication rates by anatomic site; (3) functional results as assessed by the
      Musculoskeletal Tumor Society System (MSTS); (4) differences in complication rate between
      patients treated with INM versus EPR; and (5) differences in survival in patients with
      metastatic bone disease based on disease-specific, laboratory, and demographic information.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcomes after treatment of long bone metastases with intramedullary nail versus endoprosthetic reconstruction</measure>
    <time_frame>24 months</time_frame>
    <description>The study includes the collection of clinical data (age, sex, Karnofsky score) and laboratory data related to the patient (erythrocyte sedimentation rate, C reactive protein, Alkaline phosphatase, white blood cells and hemoglobin) at the time of admission, data on the pathology (histotype, site of bone metastasis , presence of further skeletal or visceral metastases), type of surgery performed (stabilization versus resection).The objectives of this study is to examine clinical outcomes after after surgical treatment of bone metastases with a specific focus on differences in complication rate between patients treated with intramedullary nail versus endoprosthetic reconstruction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival in patients undergoing surgery for metastatic bone disease</measure>
    <time_frame>24 months</time_frame>
    <description>Provide a reliable and objective means of estimating survival in patients with metastatic bone disease based on disease-specific and laboratory tests</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding erythrocyte sedimentation rate</measure>
    <time_frame>24 months</time_frame>
    <description>erythrocyte sedimentation rate (mm/h)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding C reactive protein</measure>
    <time_frame>24 months</time_frame>
    <description>C reactive protein (mg/dl)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding Alkaline phosphatase</measure>
    <time_frame>24 months</time_frame>
    <description>Alkaline phosphatase (U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding white blood cells</measure>
    <time_frame>24 months</time_frame>
    <description>white blood cells (10/mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding hemoglobin</measure>
    <time_frame>24 months</time_frame>
    <description>hemoglobin (g/dl)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic factor regarding Karnofsky score</measure>
    <time_frame>24 months</time_frame>
    <description>Karnofsky score (0/100)</description>
  </other_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intramedullary fixation or endoprosthetic reconstruction</intervention_name>
    <description>Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bone metastases in the extremities treated with intramedullary fixation or
        endoprosthetic recosntruction for impending fracture or pathologic fracture
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with long bone metastases treated surgically with intramedullary nail or
             endoprosthetic reconstruction

        Exclusion Criteria:

          -  Patients with bone metastases of the spine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Costantino Errani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Costantino Errani, MD</last_name>
    <phone>+390516366103</phone>
    <email>costantino.errani@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Davide M Donati, MD</last_name>
    <phone>+390516366012</phone>
    <email>davidemaria.donati@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costantino Errani, MD, PhD</last_name>
      <phone>0039 051 6366103</phone>
      <email>costantino.errani@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Davide Donati, MD</last_name>
      <phone>0039 051 6366012</phone>
      <email>davidemaria.donati@ior.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Costantino Errani</investigator_full_name>
    <investigator_title>MD, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be published in the international literature at the end of the study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

